Z-L-alaninol
Need Assistance?
  • US & Canada:
    +
  • UK: +

Z-L-alaninol

* Please kindly note that our products are not to be used for therapeutic purposes and cannot be sold to patients.

Z-L-alaninol (CAS# 66674-16-6) is a useful research chemical.

Category
Amino Alcohol
Catalog number
BAT-000387
CAS number
66674-16-6
Molecular Formula
C11H15NO3
Molecular Weight
209.21
Z-L-alaninol
IUPAC Name
benzyl N-[(2S)-1-hydroxypropan-2-yl]carbamate
Synonyms
Z-L-Ala-ol; Cbz-L-Alaninol; (S)-Benzyl (1-hydroxypropan-2-yl)carbamate; N-Z-L-Alaninol; (S)-benzyl 1-hydroxypropan-2-ylcarbamate
Appearance
White to off-white powder
Purity
≥ 99 % (HPLC)
Density
1.15 g/cm3
Melting Point
81-84 °C (lit.)
Boiling Point
375.182 °C at 760 mmHg
Storage
Store at 2-8 °C
InChI
InChI=1S/C11H15NO3/c1-9(7-13)12-11(14)15-8-10-5-3-2-4-6-10/h2-6,9,13H,7-8H2,1H3,(H,12,14)/t9-/m0/s1
InChI Key
AFPHMHSLDRPUSM-VIFPVBQESA-N
Canonical SMILES
CC(CO)NC(=O)OCC1=CC=CC=C1

Z-L-alaninol, a chiral amino alcohol with unique chemical properties, finds widespread utility in diverse bioscience applications. Here are the key applications of Z-L-alaninol presented with a high degree of perplexity and burstiness:

Enantiomeric Synthesis: Serving as a cornerstone in the realm of chiral chemistry, Z-L-alaninol plays a pivotal role as a chiral building block in the synthesis of enantiomerically pure compounds. Its relevance lies in facilitating the creation of intricate molecules with precise stereochemical fidelity a critical aspect in the pharmaceutical landscape where the stereochemistry of drug molecules profoundly influences their effectiveness and safety.

Pharmaceutical Intermediates: Positioned at the crossroads of pharmaceutical innovation, Z-L-alaninol emerges as a crucial intermediate in the synthesis of diverse pharmaceutical agents. Its versatile chemical structure permits easy modifications rendering it a valuable asset in the realm of drug development. Particularly noteworthy is its significance in the synthesis of peptide-based pharmaceuticals and other bioactive compounds underscoring its role in shaping the future of therapeutic interventions.

Chiral Catalysts: Embarking on the frontier of asymmetric synthesis, Z-L-alaninol plays a pivotal role in the development of chiral catalysts and ligands. These catalysts wield the power to orchestrate enantioselective reactions directing the synthesis towards the preferential formation of a specific enantiomer. Such advancements are integral in ensuring the production of high-purity compounds a cornerstone in the chemical and pharmaceutical sectors where purity is paramount.

Biochemical Research: Delving into the intricate realm of biochemical studies, Z-L-alaninol emerges as a key player in illuminating the functions and interactions of amino alcohols. Researchers harness its properties to unravel the mysteries of enzyme mechanisms binding affinities and reaction pathways. This profound understanding aids in deciphering fundamental biological processes and fosters the development of novel biochemical assays paving the way for groundbreaking discoveries in the field of bioscience.

1. Anti-progressive Effects of a Series of Glycinyl and Alaninyl Triazolyl-oxazolidinones on Kelly Neuroblastoma Cell Line
Nada A Al-Hasawi, Oludotun A Phillips, Fatma Al-Awadhi, Leyla H Sharaf, Sanaa A Amine, Ladislav Novotny Anticancer Res. 2020 Sep;40(9):5125-5140. doi: 10.21873/anticanres.14516.
Background/aim: Neuroblastoma (NB), the most common extracranial malignant childhood tumor accounts for about 15% of cancer-related deaths in children. Despite the intensive treatment of patients with high-risk scarification of NB, clinical outcomes indicate tumor recurrence greater than 50% and late severe adverse effects. Oxazolidinones are 5-membered heterocyclic compounds with antibacterial activity against resistant bacterial strains. Structural modifications around the oxazolidinone moiety have resulted in derivatives with anti-cancer properties against proliferation, motility, and invasion of breast cancer cells. This study aimed to examine the anti-cancer potential of novel oxazolidinones against a model of a neuroblastoma cell line. Materials and methods: Newly synthesized and characterized triazolyl-oxazolidinone derivatives were incubated with neuroblastoma Kelly cells. The anti-proliferation and anti-progression effects of the compounds were evaluated by MTT, and adhesion with migration assays. Results: The 5-nitrofuroyl glycinyl-oxazolidinone containing 4-methyltriazolyl group demonstrated the most potent activity with an IC50=6.52 μM. Furthermore, the D-isomer of 5-nitrothiophenecarbonyl alaninyl containing derivative reduced the adhesion to fibronectin by 56.34%, while the D-isomer of 5-nitrofuroyl alaninyl derivative reduced the migration of Kelly cells by 29.14%. Conclusion: The presence of the 4-methyltriazolyl moiety seems to enhance the anti-proliferative property of triazolyl-oxazolidinone derivatives, as demonstrated by PH-145. There is little or no effect of the stereochemistry of the alanine side-chain on the antiproliferative effect, as demonstrated by the 5-nitrofuroyl D- and L-alaninyl containing derivatives with similar IC50 values. The observed differences in the inhibition of adhesion and migration by the oxazolidinones on Kelly cells provide a new therapeutic approach that needs further investigation.
2. Structure-Antibacterial Activity Relationships of N-Substituted-( d-/ l-Alaninyl) 1 H-1,2,3-Triazolylmethyl Oxazolidinones
Oludotun Adebayo Phillips, Edet Ekpenyong Udo, Roselyn Jennifer D'silva Sci Pharm. 2018 Sep 26;86(4):E42. doi: 10.3390/scipharm86040042.
Bacterial resistance towards the existing class of antibacterial drugs continues to increase, posing a significant threat to the clinical usefulness of these drugs. These increasing and alarming rates of antibacterial resistance development and the decline in the number of new antibacterial drugs' approval continue to serve as a major impetus for research into the discovery and development of new antibacterial agents. We synthesized a series of d-/l-alaninyl substituted triazolyl oxazolidinone derivatives and evaluated their antibacterial activity against selected standard Gram-positive and Gram-negative bacterial strains. Overall, the compounds showed moderate to strong antibacterial activity. Compounds 9d and 10d (d- and l-alaninyl derivatives bearing the 3,5-dinitrobenzoyl substituent), 10e (l-alaninyl derivative bearing the 5-nitrofurancarbonyl group) and 9f and 10f (d- and l-alaninyl derivatives bearing the 5-nitrothiophene carbonyl moiety) demonstrated antibacterial activity (MIC: 2 µg/mL) against Staphylococcus aureus, Staphylococcus epidermidis, Enterococcus faecalis and Moraxella catarrhalis standard bacterial strains. No significant differences were noticeable between the antibacterial activity of the d- and l-alaninyl derivatives as a result of the stereochemistry of the compounds.
3. The First 5'-Phosphorylated 1,2,3-Triazolyl Nucleoside Analogues with Uracil and Quinazoline-2,4-Dione Moieties: A Synthesis and Antiviral Evaluation
Dmitry A Tatarinov, et al. Molecules. 2022 Sep 21;27(19):6214. doi: 10.3390/molecules27196214.
A series of 5'-phosphorylated (dialkyl phosphates, diaryl phosphates, phosphoramidates, H-phosphonates, phosphates) 1,2,3-triazolyl nucleoside analogues in which the 1,2,3-triazole-4-yl-β-D-ribofuranose fragment is attached via a methylene group or a butylene chain to the N-1 atom of the heterocycle moiety (uracil or quinazoline-2,4-dione) was synthesized. All compounds were evaluated for antiviral activity against influenza virus A/PR/8/34/(H1N1). Antiviral assays revealed three compounds, 13b, 14b, and 17a, which showed moderate activity against influenza virus A (H1N1) with IC50 values of 17.9 μM, 51 μM, and 25 μM, respectively. In the first two compounds, the quinazoline-2,4-dione moiety is attached via a methylene or a butylene linker, respectively, to the 1,2,3-triazole-4-yl-β-D-ribofuranosyl fragment possessing a 5'-diphenyl phosphate substituent. In compound 17a, the uracil moiety is attached via the methylene unit to the 1,2,3-triazole-4-yl-β-D-ribofuranosyl fragment possessing a 5'-(phenyl methoxy-L-alaninyl)phosphate substituent. The remaining compounds appeared to be inactive against influenza virus A/PR/8/34/(H1N1). The results of molecular docking simulations indirectly confirmed the literature data that the inhibition of viral replication is carried out not by nucleoside analogues themselves, but by their 5'-triphosphate derivatives.
Online Inquiry
Verification code
Inquiry Basket